Examining Smoking Prevalence Disparities in Virginia Counties by Rurality, Appalachian Status, and Social Vulnerability, 2011-2019

Appalachian Primary Care Patients' Quit Readiness and Tobacco Treatment Receipt

INTRODUCTION

Healthcare providers should facilitate smoking cessation, and primary care is an ideal setting for delivering this evidence-based care. This study's objective was to describe readiness to quit smoking combustible cigarettes among adult Appalachian primary care patients and determine their providers' implementation of an established tobacco treatment model.

METHODS

As part of a randomized clinical trial, 298 providers in 10 health systems across 4 states received tobacco treatment training. Periodically between January 2022 and June 2023, anonymous surveys were distributed to patients after primary care visits. The survey included questions about demographics, visit type, smoking status, readiness to quit, and provider behavior related to tobacco treatment implementation. In 2023, descriptive statistics, bivariate tests and logistic regression models were conducted.

RESULTS

Among 1,242 survey respondents, 34.1% reported current smoking. Among those who reported current smoking, 13.9% expressed readiness to quit within the next 30 days and 15.3% reported readiness in 1-6 months while 36.7% indicated "never" wanting to quit. Nearly all providers asked respondents about smoking status (96.9%) and advised them to quit (89.8%); fewer providers engaged in cessation assistance by discussing behavioral counseling, discussing medication options, and/or prescribing medication (25.1%-64.6% across behaviors). Provider behavior was most consistently associated with patient age and visit type.

CONCLUSIONS

Nearly one third of Appalachian patients who smoke reported readiness to quit within 6 months and nearly all received advice to quit from their provider. Patients would benefit from more intensive tobacco treatment delivery in primary care settings, with a focus on assisting with quit attempts.

Unveiling rural and Appalachian disparities in cigarette smoking through the social vulnerability index and other county-level characteristics

PURPOSE

Mitigating tobacco-related disparities in the Appalachian region and rural areas is crucial. This study seeks to gauge cigarette smoking prevalence in Virginia counties, uncover rurality and Appalachian-linked disparities, and explore local drivers of these gaps.

METHOD

A 2011-2019 Virginia BRFSS data were used to estimate county-level cigarette smoking rates in adults aged 18 or older. Counties were categorized as urban/rural and Appalachian/non-Appalachian, with a focus on rural-Appalachian. Disparities in cigarette smoking rates and associated factors were analyzed via the Blinder-Oaxaca decomposition method. The study assessed 4 dimensions of the Centers for Disease Control and Prevention's social vulnerability index (SVI): socioeconomic, minority status, household composition, and housing. Additionally, county-specific factors such as tobacco agriculture, physician availability, coal mining, and tobacco retailer density were examined.

FINDINGS

Rural areas exhibited a 6.18% higher cigarette smoking prevalence compared to urban areas (P<.001). SVI dimensions accounted for 53.2% of the disparity, county features explained 16.4%, and 30.4% remained unexplained. Appalachian areas had a 6.79% higher cigarette smoking prevalence than non-Appalachian areas (P<.001). SVI dimensions explained 51.4% of the disparity, county features accounted for 21.8%, leaving 26.8% unexplained. Rural-Appalachian areas showed a 7.8% higher cigarette smoking prevalence (P<.001). SVI dimensions contributed to 51.7% of the disparity, county features explained 9.6%, and 38.7% remained unexplained.

CONCLUSIONS

Substantial disparities in cigarette smoking prevalence exist in underserved areas of Virginia, including rural, Appalachian, and rural-Appalachian regions. While SVI dimensions, physician availability, tobacco agriculture, and coal mining contribute, yet notable gaps remain unexplained. Targeted interventions must tackle unique challenges in disadvantaged areas to reduce smoking and promote health equity.

Testing the feasibility of the QuitAid smoking cessation intervention in a randomized factorial design in an independent, rural community pharmacy

BACKGROUND

Adult smoking rates in the USA are highest in economically depressed rural Appalachia. Pharmacist-delivered tobacco cessation support that incorporates medication therapy management (such as the QuitAid intervention) is a promising approach to address this need.

METHODS

Twenty-four adult smokers recruited between September and November 2021 through an independent pharmacy in rural Appalachia were randomized in a non-blinded 2 × 2 × 2 factorial design to (1) pharmacist delivered QuitAid intervention (yes vs. no); (2) combination nicotine replacement therapy (NRT) gum + NRT patch (vs. NRT patch); and/or (3) 8 weeks of NRT (vs. standard 4 weeks). Participants received 4 weeks of NRT patch in addition to the components to which they were assigned. Participants completed baseline and 3-month follow-up assessments. Primary outcomes were feasibility of recruitment and randomization, retention, treatment adherence, and fidelity.

RESULTS

Participants were recruited in 7 weeks primarily through a referral process, commonly referred to as ask-advise-connect (61%). Participants were on average 52.4 years old, 29.2% were male and the majority were white (91.6%) and Non-Hispanic (91.7%). There was a high level of adherence to the interventions, with 85% of QuitAid sessions completed, 83.3% of the patch used, and 54.5% of gum used. Participants reported a high level of satisfaction with the program, and there was a high level of retention (92%).

CONCLUSIONS

This demonstration pilot randomized controlled study indicates that an ask-advise-connect model for connecting rural smokers to smoking cessation support and providing QuitAid for smoking cessation is feasible and acceptable among rural Appalachian smokers and independent pharmacists. Further investigation into the efficacy of a pharmacist-delivered approach for smoking cessation is needed.

TRIAL REGISTRATION

The trial was retrospectively registered at ClinicalTrials.gov. Trial #: NCT05649241.